Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2021 Jan-Feb;15(1):215-220.
doi: 10.1016/j.dsx.2020.12.033. Epub 2020 Dec 29.

Glycemic parameters in patients with new-onset diabetes during COVID-19 pandemic are more severe than in patients with new-onset diabetes before the pandemic: NOD COVID India Study

Affiliations
Comparative Study

Glycemic parameters in patients with new-onset diabetes during COVID-19 pandemic are more severe than in patients with new-onset diabetes before the pandemic: NOD COVID India Study

Amerta Ghosh et al. Diabetes Metab Syndr. 2021 Jan-Feb.

Abstract

Background and aims: It is not known if new onset diabetes during Coronavirus-19 disease (COVID-19; NOD COVID) is phenotypically or biochemically different than new onset diabetes before COVID-19 (NOD).

Methods: All adults diagnosed with new onset diabetes from during the time of COVID-19 were compared with new onset diabetes prior to COVID-19 from two tertiary care hospitals in Chennai and Delhi. RTPCR test for SARS-CoV-2 virus was done as appropriate, and COVID-19 antibody test was done in all other NOD COVID patients.

Result: A total of 555 patients with new onset diabetes were included in the study (282 NOD and 273 NOD COVID patients). Patients with NOD COVID had higher fasting and post prandial blood glucose and glycated hemoglobin levels vs. NOD patients. Both the groups had high average body mass index; ∼28 kg/m2. Interestingly, fasting C-peptide levels were significantly higher in the NOD COVID group vs. NOD group. There was no difference in C-peptide levels or glycemic parameters between the COVID-19 antibody positive and negative NOD COVID cases.

Conclusion: Individuals who were diagnosed with diabetes during COVID-19 epidemic (NOD COVID) do not significantly differ from those diagnosed before COVID-19 in symptomatology, phenotype, and C-peptide levels but they had more severe glycemia.

Keywords: COVID-19; COVID-19 antibody; Diabetes; New-onset diabetes; Type 2 diabetes.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors do not mention any conflict of interest regarding this article.

Figures

Fig. 1
Fig. 1
Symptoms at onset of diabetes before and during COVID-19 i.e. in patients with NOD vs. NOD COVID.
Fig. 2
Fig. 2
Stress levels before and during COVID-19 i.e in NOD patients vs. NOD COVID patients.

References

    1. Gupta R., Misra A. COVID19 in South Asians/Asian Indians: heterogeneity of data and implications for pathophysiology and research. Diabetes Res Clin Pract. 2020 Jul;165:108267. - PMC - PubMed
    1. Singh A.K., Misra A. Impact of COVID-19 and comorbidities on health and economics: focus on developing countries and India. Diabetes Metab Syndr. 2020;14(6):1625–1630. - PMC - PubMed
    1. Gupta A., Madhavan M.V., Sehgal K., Nair N., Mahajan S., Sehrawat T.S. Extrapulmonary manifestations of COVID-19. Nat Med. 2020;26(7):1017–1032. 2020/07/01. - PMC - PubMed
    1. Rubino F., Amiel S.A., Zimmet P., Alberti G., Bornstein S., Eckel R.H. New-onset diabetes in covid-19. N Engl J Med. 2020;383(8):789–790. - PMC - PubMed
    1. Krishna S.V., Sunil K., Prasad R.D., Modi K.D. Precipitation of new onset diabetes by H1N1 infection. Indian J Endocrinol Metab. 2012;16(Suppl 2):S438–S440. - PMC - PubMed